TScan Therapeutics GAAP EPS of -$0.18 beats by $0.06, revenue of $2.57M beats by $0.15M
Source: SeekingAlpha
2026-03-04 11:54:32 ET
More on TScan Therapeutics
- Seeking Alpha’s Quant Rating on TScan Therapeutics
- Historical earnings data for TScan Therapeutics
- Financial information for TScan Therapeutics
Read the full article on Seeking Alpha
For further details see:
TScan Therapeutics GAAP EPS of -$0.18 beats by $0.06, revenue of $2.57M beats by $0.15M
TScan Therapeutics Inc.
NASDAQ: TCRX
TCRX Trading
-9.75% G/L:
$1.065 Last:
336,301 Volume:
$1.15 Open:
TCRX Latest News
March 04, 2026 07:00:00 am
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026 07:00:00 am
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA(TM) Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
February 25, 2026 07:00:00 am
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
TCRX Stock Data
$56,461,416
43,043,353
4.2%
36
N/A
Biotechnology & Life Sciences
Healthcare
US
Waltham
